Apollomics is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies that harness the immune system and target specific molecular pathways to inhibit cancer. The company develops novel treatments for difficult to treat cancers using targeted immunooncology and other innovative approaches. Its pipeline includes tumor inhibitors and immunooncology drug candidates targeting indications such as lung cancer brain cancer and solid tumors. Apollomics is incorporated in the Cayman Islands with headquarters in Foster City California and additional operations in Hangzhou China. It operates through subsidiaries in Australia Hong Kong and China. The company seeks to improve response rates and reduce chemo resistance and toxicity compared with current standards.

Apollomics generates revenue primarily through licensing and collaboration agreements that include upfront payments milestone payments and royalties on net sales of partnered product candidates. The company has entered into agreements with partners such as LaunXP for the development and commercialization of vebreltinib in combination with an EGFR inhibitor receiving up to ten million dollars in upfront fees. It also retains rights to its product candidates outside China and expects future revenue from commercialization of approved therapies. Revenue may also arise from milestone payments and royalties under arrangements with Genor CTTQ and other collaborators for its immunooncology programs.

The company operates through the following segments: Tumor Inhibitors and Immunooncology Product Candidates.

• Tumor Inhibitors focuses on small molecule inhibitors targeting uncontrolled growth signaling pathways in cancer cells including the lead candidate vebreltinib a selective cMet inhibitor and APL-102 another tumor inhibitor aiming to overcome treatment resistance and chemo resistance in indications such as non small cell lung cancer glioma and other solid tumors.

• Immunooncology Product Candidates comprises monoclonal antibodies and a cancer vaccine designed to engage the immune system against cancer including APL-501 an anti PD1 antibody APL-502 an anti PDL1 antibody and APL-801 a novel cancer vaccine targeting the gastrin immunogen to enhance anti tumor immune response.

Apollomics occupies a niche in the competitive oncology biotechnology landscape by focusing on cMet driven tumors and immunooncology approaches where it faces competition from large pharmaceutical companies such as AbbVie AstraZeneca EMD Serono Johnson & Johnson and Novartis as well as numerous biotech firms developing similar checkpoint inhibitors and targeted therapies. Its competitive advantages stem from a science driven R&D engine a biomarker driven patient selection strategy a growing patent portfolio covering nine therapeutic targets and an experienced global management team with expertise in clinical development across the United States China and Europe.

The company serves patients hospitals and research institutions through its partnerships with pharmaceutical companies and collaboration partners. Specific customer names include Avistone Genor CTTQ LaunXP and RevMab with whom Apollomics has entered into licensing collaboration and co development agreements for its tumor inhibitor and immunooncology product candidates.